Deciphera Pharmaceuticals (DCPH)
(Delayed Data from NSDQ)
$25.36 USD
-0.01 (-0.04%)
Updated May 10, 2024 04:00 PM ET
After-Market: $25.36 0.00 (0.00%) 7:58 PM ET
3-Hold of 5 3
F Value B Growth C Momentum D VGM
Brokerage Reports
0 items in cart
Deciphera Pharmaceuticals, Inc. [DCPH]
Reports for Purchase
Showing records 21 - 40 ( 98 total )
Company: Deciphera Pharmaceuticals, Inc.
Industry: Medical - Biomedical and Genetics
Company: Deciphera Pharmaceuticals, Inc.
Industry: Medical - Biomedical and Genetics
Provider: Zacks Investment Research
Analyst: Research Department
Company: Deciphera Pharmaceuticals, Inc.
Industry: Medical - Biomedical and Genetics
Company: Deciphera Pharmaceuticals, Inc.
Industry: Medical - Biomedical and Genetics
Provider: Zacks Investment Research
Analyst: Research Department
Company: Deciphera Pharmaceuticals, Inc.
Industry: Medical - Biomedical and Genetics
Qinlock Expansion Steady; MOTION Study Data in 4Q23; Reit. Buy and $25 PT
Provider: H.C. Wainwright & Co., Inc.
Analyst: FEIN A
Company: Deciphera Pharmaceuticals, Inc.
Industry: Medical - Biomedical and Genetics
Company: Deciphera Pharmaceuticals, Inc.
Industry: Medical - Biomedical and Genetics
Provider: Zacks Investment Research
Analyst: Research Department
Company: Deciphera Pharmaceuticals, Inc.
Industry: Medical - Biomedical and Genetics
Provider: Zacks Investment Research
Analyst: Research Department
Company: Deciphera Pharmaceuticals, Inc.
Industry: Medical - Biomedical and Genetics
Provider: Zacks Investment Research
Analyst: Research Department
Company: Deciphera Pharmaceuticals, Inc.
Industry: Medical - Biomedical and Genetics
Potential for Qinlock and Switch-Control Platform Continues to Rise; Reit. Buy and $25 PT
Provider: H.C. Wainwright & Co., Inc.
Analyst: FEIN A
Company: Deciphera Pharmaceuticals, Inc.
Industry: Medical - Biomedical and Genetics
Provider: Zacks Investment Research
Analyst: Research Department
Company: Deciphera Pharmaceuticals, Inc.
Industry: Medical - Biomedical and Genetics
Provider: Zacks Investment Research
Analyst: Research Department
Company: Deciphera Pharmaceuticals, Inc.
Industry: Medical - Biomedical and Genetics
Provider: Zacks Investment Research
Analyst: Research Department
Company: Deciphera Pharmaceuticals, Inc.
Industry: Medical - Biomedical and Genetics
Expect QINLOCK Growth and Positive Vimseltinib Data to Drive Near/Long-Term Value; Reit. Buy and $25 PT
Provider: H.C. Wainwright & Co., Inc.
Analyst: FEIN A
Company: Deciphera Pharmaceuticals, Inc.
Industry: Medical - Biomedical and Genetics
HCW 2023 Top Picks: Seize the Opportunities
Provider: H.C. Wainwright & Co., Inc.
Analyst: Research Department
Company: Deciphera Pharmaceuticals, Inc.
Industry: Medical - Biomedical and Genetics
Provider: Zacks Investment Research
Analyst: Research Department
Company: Deciphera Pharmaceuticals, Inc.
Industry: Medical - Biomedical and Genetics
A ctDNA Retrospective Analysis of INTRIGUE Brings 2L-GIST Back Into Focus; Reiterate Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: FEIN A
Company: Deciphera Pharmaceuticals, Inc.
Industry: Medical - Biomedical and Genetics
Provider: Zacks Investment Research
Analyst: Research Department
Company: Deciphera Pharmaceuticals, Inc.
Industry: Medical - Biomedical and Genetics
Provider: Zacks Investment Research
Analyst: Research Department
Company: Deciphera Pharmaceuticals, Inc.
Industry: Medical - Biomedical and Genetics
A Look at Assets Beyond Qinlock Reaffirms Our Conviction Toward the Pipeline; Reit. Buy and $25 PT
Provider: H.C. Wainwright & Co., Inc.
Analyst: FEIN A